enGene's Gene Therapy Achieves 63% Complete Response Rate in Pivotal Bladder Cancer Trial
核心洞察
enGene's detalimogene voraplasmid demonstrated a 63% complete response rate at three months in high-risk, BCG-unresponsive non-muscle invasive bladder cancer (搜索) patients in the pivotal LEGEND Phase II trial.
The complete response rate improved from 56% at three months to 62% at six months, with all five patients completing nine-month assessments maintaining complete response.
The gene therapy showed favorable safety profile with 42% of patients experiencing treatment-related adverse events, mostly Grade 1/2 severity, supporting planned BLA submission in H2 2026.
enGene's investigational gene therapy for high-risk, Bacillus Calmette-Guérin (搜索) (BCG)-unresponsive non-muscle invasive bladder cancer (搜索) (NMIBC (搜索)) has demonstrated a 63% complete response rate in preliminary data from its pivotal Phase II LEGEND study. The promising results sent the company's stock soaring 42% to $8.55 per share at market open on November 11, reflecting investor confidence in the therapeutic potential of detalimogene voraplasmid.
Strong Efficacy Signal Across Multiple Timepoints
The LEGEND study (NCT04752722) enrolled 62 patients for the three-month analysis, with 37 patients reaching the six-month mark and five patients completing nine-month assessments. The data revealed a progressive improvement in complete response rates over time, starting at 56% at three months and climbing to 62% at six months. Notably, four patients successfully converted to complete response following reinduction therapy, and all five patients who reached the nine-month evaluation maintained their complete response.
"We are pleased to report an improved six-month CR rate for patients being treated with detalimogene under our amended protocol," said Dr. Hussein Sweiti, enGene's chief medical officer. "With a competitive preliminary efficacy profile and potential for best-in-class tolerability and ease of use, we believe detalimogene could emerge as the first-line therapy for patients with high-risk, BCG-unresponsive NMIBC (搜索)."
Protocol Amendment Drives Improved Outcomes
The November data represents a significant improvement from earlier preliminary results released in September 2024, which showed a 55% complete response rate in 21 patients enrolled before a protocol amendment. An additional 10 patients were enrolled under the prior protocol, bringing the total to 31 patients in this earlier cohort. The enhanced efficacy observed in the amended protocol cohort underscores the importance of optimized treatment parameters in gene therapy applications.
Favorable Safety Profile Supports Development Timeline
Safety data from the entire patient population demonstrated a manageable adverse event profile, with 42% of patients experiencing treatment-related adverse events (TRAEs). The majority of these events were Grade 1/2 in severity, with only three patients experiencing Grade 3 TRAEs. Treatment interruptions occurred in just 1.6% of patients, while only 0.8% discontinued dosing due to treatment-related adverse events.
The trial has completed enrollment of 125 patients across three distinct cohorts: 30 NMIBC (搜索) patients with carcinoma in situ (搜索) (CIS) who are naïve to BCG treatment, 45 high-risk NMIBC patients with CIS who have been exposed to BCG but have not received adequate treatment, and 36 BCG-unresponsive high-risk NMIBC patients with papillary-only disease.
Regulatory Path and Market Potential
The positive preliminary data continues to support enGene's planned biologics license application (BLA) submission in the second half of 2026. The company plans to engage with the FDA regarding a statistical analysis plan to determine which patients will be included in the final efficacy evaluable population. A data update from the pivotal cohort is also expected during the same timeframe.
If approved, GlobalData (搜索) forecasts detalimogene voraplasmid could achieve $731 million in patient-based sales by 2033. This projection comes amid significant growth expectations for the broader bladder cancer (搜索) market across eight major markets, which is projected to expand from $3 billion in 2023 to $16 billion in 2033, representing a compound annual growth rate of 18%.
Competitive Landscape Evolution
The NMIBC (搜索) treatment landscape is experiencing rapid evolution, with UroGen (搜索) recently gaining approval for Zusduri (搜索) (mitomycin) in low-grade intermediate-risk NMIBC. Several other therapies are advancing through Phase III trials, including MSD's Keytruda, indicating a potentially more diverse treatment landscape for patients with this challenging condition.
The strong preliminary efficacy and favorable safety profile of detalimogene voraplasmid positions enGene competitively in this expanding market, particularly given the significant unmet medical need in BCG-unresponsive NMIBC (搜索) patients who currently have limited therapeutic options.